Modern crises, modern solutions.
Tech talk. As obesity and diabetes surge, lifestyle interventions are being prescribed alongside GLP-1s — with CGMs and predictive tech emerging as behavior change tools.
FDA x CGM. Signos gained FDA clearance for its Dexcom-powered weight loss program, logging glucose response to food, sleep, stress, and exercise. Coaching members to ~8% of body weight in six months, the platform now links to nonprescription CGM Stelo and is pushing for insurance coverage.
Double down. Twin Health just raised $53M at a $950M valuation for its digital twin model, integrating smartwatch, CGM, and device data to coach lifestyle change.
Publishing results, 71% of members reversed diabetes, while 81% eliminated GLP-1 use.
In the mix. Mainstreaming metabolic health, Levels synced with Dexcom’s Stelo last week but remains classified as wellness, not medical-grade. Meanwhile, nutrition-focused Virta Health now prescribes GLP-1s but also promises to curb their usage.
Punchline: With or without GLP-1s, the companies building metabolic health’s operating systems could control the on-ramp to lasting health.
